Mkt Advisors LLC Bristol Myers Squibb CO Transaction History

Mkt Advisors LLC

$213 Million
Q3 2024

A detailed history of Mkt Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mkt Advisors LLC holds 7,149 shares of BMY stock, worth $412,926. This represents 0.17% of its overall portfolio holdings.

Number of Shares

7,149

Previous 7,265 1.6%

Holding current value

$412,926

Previous $301,000 22.59%

% of portfolio

0.17%

Previous 0.15%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 07, 2024	SELL	$39.66 - $51.75 $4,600 - $6,003	-116 Reduced 1.6%	7,149 $369,000
Q2 2024 Jul 12, 2024	SELL	$40.25 - $52.99 $17,911 - $23,580	-445 Reduced 5.77%	7,265 $301,000
Q1 2024 Apr 15, 2024	BUY	$47.98 - $54.4 $17,032 - $19,312	355 Added 4.83%	7,710 $418,000
Q4 2023 Jan 12, 2024	SELL	$48.48 - $57.85 $4,023 - $4,801	-83 Reduced 1.12%	7,355 $377,000
Q3 2023 Oct 12, 2023	SELL	$57.89 - $64.73 $26,513 - $29,646	-458 Reduced 5.8%	7,438 $431,000
Q2 2023 Aug 01, 2023	SELL	$63.71 - $70.74 $127,101 - $141,126	-1,995 Reduced 20.17%	7,896 $504,000
Q1 2023 Apr 10, 2023	SELL	$65.71 - $74.53 $4,074 - $4,620	-62 Reduced 0.62%	9,891 $685,000
Q4 2022 Jan 19, 2023	SELL	$68.48 - $81.09 $19,311 - $22,867	-282 Reduced 2.76%	9,953 $0
Q3 2022 Oct 20, 2022	SELL	$0.13 - $76.84 $3 - $1,997	-26 Reduced 0.25%	10,235 $728,000
Q2 2022 Aug 09, 2022	SELL	$72.62 - $79.98 $8,351 - $9,197	-115 Reduced 1.11%	10,261 $790,000
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $90,437 - $108,442	1,471 Added 16.52%	10,376 $791,000
Q4 2021 Feb 11, 2022	BUY	$53.63 - $62.52 $477,575 - $556,740	8,905 New	8,905 $554,000

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mkt Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mkt Advisors LLC with notifications on news.

Account